Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer
NEW YORK, Dec. 12, 2023 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid’s EsoGuard® Esophageal DNA test to detect esophageal precancer.
Related news for (PAVM)
- PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement
- PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
- PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
- PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing